Elligo Health Research Company Profile

Background

Overview

Elligo Health Research is an integrated research organization (IRO) founded in 2016, headquartered in Austin, Texas. The company specializes in accelerating clinical trials by connecting patients, physicians, and healthcare systems through innovative research methodologies. By embedding research into routine care, Elligo aims to make clinical trials more accessible, efficient, and inclusive.

Mission and Vision

Elligo's mission is to ensure that all patients have access to clinical trials as a care option, thereby advancing the development of new pharmaceutical, biotechnology, medical device, and diagnostic products. The company's vision is to transform the clinical research landscape by integrating research seamlessly into healthcare, enhancing patient engagement, and improving trial efficiency.

Primary Area of Focus

Elligo focuses on facilitating clinical trials by leveraging electronic health record (EHR) data, proprietary technologies, and a vast network of healthcare providers. This approach aims to streamline patient recruitment, enhance retention, and reduce operational risks associated with clinical studies.

Industry Significance

In the clinical research industry, Elligo stands out by bridging the gap between healthcare and research. Its model enhances patient access to trials, improves diversity in research populations, and accelerates the development of new therapies. By integrating research into everyday care, Elligo contributes to more efficient and patient-centric clinical trials.

Key Strategic Focus

Core Objectives

• Enhancing Patient Access: Facilitate broader participation in clinical trials by integrating research into routine healthcare.

• Improving Trial Efficiency: Streamline clinical trial processes to reduce costs and time to market for new therapies.

• Ensuring Data Integrity: Utilize EHR data to maintain high standards of data quality and compliance.

Specific Areas of Specialization

• Clinical Trial Management: Oversee all phases of clinical trials, ensuring adherence to protocols and regulatory requirements.

• Patient Recruitment and Engagement: Develop strategies to identify and enroll eligible patients, enhancing retention and compliance.

• Site Development and Support: Provide infrastructure, staffing, and operational support to research sites, including both traditional and decentralized models.

Key Technologies Utilized

• IntElligo Research Stack™: A proprietary clinical technology platform that integrates EHR data to identify and match patients to clinical trials efficiently.

• Study Marketplace™: A technology that simplifies trial placement by connecting sponsors with a network of research-ready sites.

Primary Markets or Conditions Targeted

Elligo's services span various therapeutic areas, including general medicine, endocrinology, dermatology, neurology, pulmonology, and cardiology. The company also focuses on emerging fields such as psychedelic research, offering specialized solutions to advance studies in this area.

Financials and Funding

Funding History

• Series B Funding (March 2018): Raised $16 million to support the expansion of its research capabilities.

• Series C Funding (May 2019): Secured an additional $20 million, led by Piper Jaffray Merchant Banking, to further enhance patient access to clinical trials.

Total Funds Raised

As of May 2026, Elligo Health Research has raised a total of $36 million in funding.

Notable Investors

• Piper Jaffray Merchant Banking: Led the Series C funding round in 2019.

• Hatteras Venture Partners: Participated in the Series C funding round.

• Noro-Moseley Partners: Also participated in the Series C funding round.

Intended Utilization of Capital

The funds raised have been allocated to expand Elligo's research infrastructure, enhance patient recruitment and engagement strategies, and develop proprietary technologies to streamline clinical trial processes.

Pipeline Development

Elligo Health Research has supported over 1,000 studies across more than 80 sponsors and contract research organizations (CROs) in 30 countries. The company's pipeline includes trials in various therapeutic areas, with a focus on integrating research into routine care to improve patient outcomes.

Technological Platform and Innovation

Proprietary Technologies

• IntElligo Research Stack™: A clinical technology platform that integrates EHR data to identify and match patients to clinical trials efficiently.

• Study Marketplace™: A technology that simplifies trial placement by connecting sponsors with a network of research-ready sites.

Significant Scientific Methods

• EHR Data Integration: Utilizing electronic health records to identify and match patients to clinical trials, enhancing recruitment efficiency.

• Decentralized and Hybrid Trials: Implementing trial models that allow for remote patient participation, increasing accessibility and diversity.

Leadership Team

• Barry Simms, MBA – Chief Executive Officer: Joined Elligo in 2023, bringing a renewed focus on operational excellence, therapeutic alignment, and strategic innovation.

• Brandon Cormier – Chief Commercial Officer: Oversees commercial strategy and partnerships, driving growth and market expansion.

• Karen Flaherty, CPA – Chief Financial Officer: Manages financial operations, ensuring fiscal responsibility and strategic investment.